Voyager Therapeutics, Inc. Marketable Securities (Current)
Voyager Therapeutics, Inc. (VYGR) had Marketable Securities (Current) of $80.57 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-06
- 2026-06-30: Marketable Securities, Current $80.57M.
- 2026-03-31: Marketable Securities, Current $98.17M.
- 2025-12-31: Marketable Securities, Current $131.15M.
- 2025-09-30: Marketable Securities, Current $163.81M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $80.57M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $98.17M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $131.15M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $163.81M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $171.65M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $161.26M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $195.32M 10-K · filed 2026-03-09 |
| 2024-09-30 | $232.84M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $294.89M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $256.49M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $162.07M 10-K · filed 2025-03-11 |
| 2023-09-30 | $187.67M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $28.45M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $4.99M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $19.89M 10-K · filed 2024-02-28 |
| 2022-09-30 | $34.78M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $69.73M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $34.96M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $15.11M 10-K · filed 2023-03-07 |
| 2021-09-30 | $10.02M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $25.14M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $43.71M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $76.70M 10-K · filed 2022-03-08 |
| 2020-09-30 | $52.57M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $85.35M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $85.70M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $195.49M 10-K · filed 2021-02-25 |
| 2019-09-30 | $224.76M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $247.58M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $245.24M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $108.95M 10-K · filed 2020-03-03 |
| 2018-09-30 | $137.46M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $136.51M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $77.83M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $137.52M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |